Influence ofGSTM1,GSTT1, andGSTP1Polymorphisms on Type 2 Diabetes Mellitus and Diabetic Sensorimotor Peripheral Neuropathy Risk

Stoian, Adina; Bănescu, Claudia; Bălaşa, Rodica; Moţăţăianu, Anca; Stoian, M; Moldovan, Valeriu; Voidăzan, Septimiu; Dobreanu, Minodora

doi:10.1155/2015/638693

Cited by 46 publications

(50 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although, regression analysis in T2DM patients show that GSTM1 and GSTT1 genotypes are not associated with T2DM retinopathy development in the Southern Iranian population. Stoian A et al (2015) data suggest that GSTP1 gene polymorphisms may contribute to the development of T2DM in Romanian population. GSTM1, GSTT1, and GSTP1 gene polymorphisms are not associated with susceptibility of developing diabetic neuropathy in T2DM patients.…”

Section: Aims and Objectivementioning

confidence: 83%

Role of Glutathione S Transferases Polymorphism in type 2 diabetes mellitus, with and without micro vascular complications

Mishra¹

2017

JMSCR

View full text Add to dashboard Cite

Section: Aims and Objectivementioning

confidence: 83%

Role of Glutathione S Transferases Polymorphism in type 2 diabetes mellitus, with and without micro vascular complications

Mishra¹

2017

JMSCR

View full text Add to dashboard Cite

“…15,16,20,33 For example, Stoian and colleagues (2015) reported no significant association between the GSTM1 and GSTT1 null genotypes and the development of type 2 diabetes mellitus (T2DM) in a Romanian patient population compared with a healthy control group (P = .96 for GSTM1; P = .21 for GSTT1). 23 Porojan and colleagues (2015) likewise found no increased frequency of the GSTM1 and GSTT1 null genotypes in the T2DM group compared with healthy controls (for GSTM1, OR = 1.44, CI = 0.85-2.45; P = .171; for GSTT1, OR = 0.85, CI = 0.44-1.67; P = .647). 34 In contrast, several studies have reported a significant association between the frequency of GSTM1 null and GSTT1 null genotypes and T2DM.…”

Section: Discussionmentioning

confidence: 95%

“…The thermal stability and enzyme activity of GSTP1 are decreased in the variant homozygote. 23,24 In the present study, we determined the genotype frequency of the GSTM1, GSTT1, and GSTP1 polymorphisms in liver transplant recipients and their association with the risk of NODM after transplant in a patient population in Iran.…”

Section: Introductionmentioning

confidence: 99%

Glutathione S-Transferase Gene Polymorphisms and the Development of New-Onset Diabetes After Liver Transplant

Musavi

Moasser²,

Zareei³

et al. 2019

Exp Clin Transplant

View full text Add to dashboard Cite

Objectives: The association between the glutathione Stransferase polymorphisms and the development of new-onset diabetes mellitus after liver transplant was studied. Materials and Methods: Peripheral blood samples were collected from 106 liver transplant patients divided into 2 groups: 52 with new-onset diabetes mellitus and 54 without new-onset diabetes mellitus; 169 healthy individuals with no clinical evidence of diabetes mellitus were selected as a control group. The multiplex polymerase chain reaction technique was used for genotyping GSTM1 and GSTT1 genes, using the cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1) gene as an internal control. The genotype of GSTP1 was determined using the restriction fragment length polymorphism-polymerase chain reaction technique. Results: The frequency of both GSTM1 null and GSTT1 null genotypes was not significantly different in liver transplant patients with new-onset diabetes mellitus compared with the control group (P = .11 for GSTM1; P = .71 for GSTT1). Also, there was no statistically significant association between the frequency of the GSTP1 genotypes in the liver transplant patients with new-onset diabetes mellitus compared with controls. Neither GSTM1 nor GSTT1 null genotypes were associated with the risk of developing new-onset diabetes mellitus (P = .22 for GSTM1; P = .56 for GSTT1). However, the frequency of the heterozygous mutation (AG) in the A313G GSTP1 polymorphism in patients with new-onset diabetes mellitus was significantly higher than in patients without new-onset diabetes mellitus (55.8% vs 7.4%; P = .00). Thus, the risk of developing new-onset diabetes mellitus was significantly higher in patients presenting with heterozygous GSTP1 genotypes (odds ratio = 15.76; 95% confidence interval = 4.53-60.28; P = .00). Conclusions: The GSTP1 AG genotype was associated with an increased susceptibility to the development of new-onset diabetes mellitus after liver transplant.

show abstract

“…Numerous GST polymorphisms have been associated with an increased or decreased susceptibility to several diseases [39,[42][43][44][45], but only a few studies examined the association of GST polymorphisms and DR in T2DM patients ( Table 1). Cilenšek et al proposed a protective effect for the GSTM1-null genotype against retinopathy [46], explained by an up-regulation of other antioxidant enzymes, such as MnSOD [47].…”

Section: Glutathione S-transferases (Gsts)mentioning

confidence: 99%

Oxidative Stress Biomarkers for Diabetic Retinopathy and Medical Management Affecting Oxidative Stress

Cilenšek¹,

Ramuš²,

Petrovič³

et al. 2016

Role of Biomarkers in Medicine

View full text Add to dashboard Cite

Changes in dietary habits and lifestyles associated with rapid economic growth have dramatically increased the incidence of diabetes and related vascular complications. Diabetic retinopathy (DR), a microvascular complication of diabetes, is associated with both environmental and genetic factors. Several metabolic abnormalities are implicated in its pathogenesis; however, the exact mechanism remains to be determined. Among them, oxidative stress is expected to play an important role.Environmental, genetic, and epigenetic factors affecting the oxidative stress responsible for DR are reviewed in this paper. The knowledge about genetic biomarkers of DR is quite extensive, whereas the awareness about epigenetics and epigenetic markers is only beginning to be understood.Modulation of epigenetic changes by pharmaceutical means may provide a potential strategy to retard the progression of DR. In addition to the intense medical management, these strategies include dietary measures (antioxidants) and the introduction of epigenetic drugs, such as inhibitors of DNA methylation and histone demethylases.

show abstract

Influence ofGSTM1,GSTT1, andGSTP1Polymorphisms on Type 2 Diabetes Mellitus and Diabetic Sensorimotor Peripheral Neuropathy Risk

Cited by 46 publications

References 44 publications

Role of Glutathione S Transferases Polymorphism in type 2 diabetes mellitus, with and without micro vascular complications

Role of Glutathione S Transferases Polymorphism in type 2 diabetes mellitus, with and without micro vascular complications

Glutathione S-Transferase Gene Polymorphisms and the Development of New-Onset Diabetes After Liver Transplant

Oxidative Stress Biomarkers for Diabetic Retinopathy and Medical Management Affecting Oxidative Stress

Contact Info

Product

Resources

About